No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
Roche Holding AG is a global healthcare enterprise with dual focuses: pharmaceuticals and diagnostics. The company maintains a significant presence in numerous countries, including its home base in Switzerland, alongside Germany, the United States, Austria, the Netherlands, the United Kingdom, France, Belgium, and various other international markets. Its pharmaceutical segment develops and supplies treatments for a wide spectrum of medical conditions, encompassing oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments, as well as specific therapies for anemia, dermatology, hemophilia, inflammatory and autoimmune conditions, and transplant patients. On the diagnostic front, Roche provides in vitro tests designed to identify various diseases like cancer, diabetes, COVID-19, hepatitis, and human papillomavirus, in addition to supplying crucial diagnostic instruments and reagents. The company was founded in Basel, Switzerland, in 1896.
www.roche.comNo one on the platform currently holds RO.SW.
No tracked institution reports a position in RO.SW as of their last filing.
No one on the platform has traded RO.SW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 25.2% | 25.2% | 29.6% | — | — | — |
| Rev. Growth % | -1.4% | 1.1% | ||||
| Profit Margin % | 20.9% | 18.9% | 19.1% | |||
| Free Cash Flow Margin % | 22.9% | 22.4% | 23.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $63.2B | +2.2% | $20.43 | $20.05–$20.80 | — | 2 |
| 2027 | $65.9B | +4.2% | $21.91 | $21.27–$22.55 | — | 2 |
| 2028 | $69.0B | +4.8% | $23.76 | $23.05–$25.22 | — | 1 |
| 2029 | $72.1B | +4.4% | $25.79 | $25.02–$27.38 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-23 | $10.20 | $8.52 | -16.5% |
| 2026-01-29 | $8.37 | $8.16 | -2.5% |
| 2025-07-24 | $10.48 | $11.11 | +6.0% |
| 2025-01-30 | $8.47 | $8.64 | +2.0% |
| 2024-07-25 | $9.20 | $10.05 | +9.2% |
| 2024-02-01 | $8.70 | $8.69 | -0.1% |
| 2023-11-29 | $10.40 | $8.88 | -14.6% |
| 2023-02-02 | $8.48 |
| $8.47 |
| -0.1% |
| $1.0B |
| — |
| GALE.SWGalenica AG | $82.40 | -0.12% | $4.1B | — |
| NOVN.SWNovartis AG | $114.76 | +0.81% | $218.1B | — |
Source: Financial Modeling Prep · peers by sector/industry